Joseph Helft, MD
Cardiovascular Disease · Bronx, NYNPI 1659478477
Payments from drug & device makers
Across 1,059 payments — averaging $460.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$187K
- Johnson & Johnson$146K
- Amgen$46K
- Boehringer Ingelheim$45K
- Pfizer$25K
- E.r. Squibb & Sons, L.L.C.$22K
- plus $18K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 147 | $186,917 |
| Johnson & Johnson | 189 | $145,796 |
| Amgen | 115 | $45,630 |
| Boehringer Ingelheim | 79 | $45,227 |
| Pfizer | 78 | $24,602 |
| E.r. Squibb & Sons, L.L.C. | 59 | $22,024 |
| Abbott | 15 | $6,140 |
| Lilly USA, LLC | 9 | $4,652 |
| AstraZeneca | 71 | $1,380 |
| Novartis | 62 | $857 |
| Merck | 31 | $664 |
| Boston Scientific | 27 | $552 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $500 |
| Edwards Lifesciences | 18 | $438 |
| Sanofi-aventis U.S. LLC | 22 | $422 |
| Lexicon Pharmaceuticals, Inc. | 29 | $369 |
| Esperion Therapeutics, Inc. | 24 | $330 |
| Bayer | 15 | $252 |
| Amarin Pharma, Inc. | 15 | $246 |
| Scpharmaceuticals Inc. | 8 | $195 |
| Kowa Pharmaceuticals America, Inc. | 13 | $192 |
| Alnylam Pharmaceuticals Inc. | 6 | $128 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $104 |
| Shockwave Medical, Inc | 1 | $97 |
| Bristol Myers Squibb | 4 | $76 |
| Arbor Pharmaceuticals, Inc. | 3 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Gilead | 2 | $30 |
| Medtronic | 2 | $29 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Heartflow, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
How this compares
$488,081 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Bronx
- Luigi di BiaseBronx$2.5M
- Michele NannaBronx$353K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.